The MYCN enigma: Significance of MYCN expression in neuroblastoma

Cancer Research

Volumn 66, Issue 5, 2006, Pages 2826-2833

  Tang, Xao X ^a   Zhao, Huaqing ^b   Kung, Bing ^b   Kim, David Y ^b   Hicks, Sakeenah L ^a   Cohn, Susan L ^c   Cheung, Nai Kong ^d   Seeger, Robert C ^e   Evans, Audrey E ^b   Ikegaki, Naohiko ^a,f  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

^f Emory Children's Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE A;

ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; COHORT ANALYSIS; GENE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; MYCN GENE; NEUROBLASTOMA; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRKA GENE;

AGE FACTORS; CELL LINE, TUMOR; COHORT STUDIES; GENE AMPLIFICATION; HUMANS; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; RECEPTOR, TRKA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33645065340     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0854     Document Type: Article

References (53)

1. Silber JH, Evans AE, Fridman M. Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Res 1991;51: 1426-33.
2. Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971;31:2098-103.
3. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-72.
4. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:581-91.
5. Hann HW, Evans AE, Siegel SE, et al. Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: the Children's Cancer Study Group experience. Cancer Res 1985;45:2843-8.
6. Shuster JJ, McWilliams NB, Castleberry R, et al. Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study. Am J Clin Oncol 1992;15:295-303.
7. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. New Engl J Med 1985; 313:1111-6.
8. Maris JM, White PS, Beltinger CP, et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 1995;55:4664-9.
9. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334: 225-30.
10. Guo C, White PS, Weiss MJ, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999;18:4948-57.
11. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243-53.
12. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340:1954-61.
13. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328:847-54.
14. Combaret V, Gross N, Lasset C, et al. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 1996;14:25-34.
15. Tang XX, Zhao H, Robinson ME, et al. Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci U S A 2000;97: 10936-41.
16. Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, Brodeur GM. Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res 2002;62:1802-8.
17. Gross N, Balmas Bourloud K, Brognara CB. MYCN-related suppression of functional CD44 expression enhances tumorigenic properties of human neuroblastoma cells. Exp Cell Res 2000;260:396-403.
18. Kohl NE, Gee CE, Alt FW. Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science 1984;226:1335-7.
19. Nisen PD, Waber PG, Rich MA, et al. N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 1988;80:1633-7.
20. Slave I, Ellenbogen R, Jung WH, et al. myc gene amplification and expression in primary human neuroblastoma. Cancer Res 1990;50:1459-63.
21. Seeger RC, Wada R, Brodeur GM, et al. Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 1988;271:41-9.
22. Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A 1984;81:4940-4.
23. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996;334: 231-8.
24. Nakagawara A, Kadomatsu K, Sato S, et al. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas. Cancer Res 1990;50:3043-7.
25. Chan HSL, Gallie BL, DeBoer G, et al. MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 1997;3:1699-706.
26. Cohn SL, London WB, Huang D, et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000;18:3604-13.
27. Alaminos M, Gerald WL, Cheung NK. Prognostic value of MYCN and ID2 overexpression in neuroblastoma. Pediatr Blood Cancer 2005;45:909-15.
28. Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 1998;16:3286-94.
29. Matsunaga T, Shirasawa H, Hishiki T, et al. Enhanced expression of N-myc messenger RNA in neuroblastomas found by mass screening. Clin Cancer Res 2000;6:3199-204.
30. Tang XX, Evans AE, Zhao H, et al. High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clin Cancer Res 1999;5: 1491-6.
31. Tang XX, Brodeur GM, Campling BG, Ikegaki N. Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma. Clin Cancer Res 1999; 5:455-60.
32. Eggert A, Brodeur GM, Ikegaki N. Relative quantitative RT-PCR protocol for TrkB expression in neuroblastoma using GAPD as an internal control. Biotechniques 2000;28:681-91.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
34. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
35. Cox DR. Regression models and lifetables. J R Stat Soc [B] 1972;74:187-220.
36. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995;23:1686-90.
37. Ikegaki N, Bukovsky J, Kennett RH. Identification and characterization of the NMYC gene product in human neuroblastoma cells by monoclonal antibodies with defined specificities. Proc Natl Acad Sci USA 1986;83: 5929-33.
38. Tang XX, Evans AE, Zhao H, Cnaan A, Brodeur GM, Ikegaki N. Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas. Med Pediatr Oncol 2001;36:80-2.
39. Schwab M, Varmus HE, Bishop JM, et al. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 1984;308:288-91.
40. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
41. Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. J Immunol 1983;130:2471-8.
42. Squire R, Fowler CL, Brooks SP, Rich GA, Cooney DR. The relationship of class I MHC antigen expression to stage IV-S disease and survival in neuroblastoma. J Pediatr Surg 1990;25:381-6.
43. Whelan JP, Chatten J, Lampson LA. HLA class I and beta 2-microglobulin expression in frozen and formaldehyde-fixed paraffin sections of neuroblastoma tumors. Cancer Res 1985;45:5976-83.
44. Tang XX Robinson ME, Riceberg JS, et al. Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma. Clin Cancer Res 2004;10:5837-44.
45. van Golen CM, Soules ME, Grauman AR, Feldman EL. N-Myc overexpression leads to decreased beta1 integrin expression and increased apoptosis in human neuroblastoma cells. Oncogene 2003;22:2664-73.
46. Lutz W, Fulda S, Jeremias I, Debatin KM, Schwab M. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene 1998;17:339-46.
47. Fulda S, Lutz W, Schwab M, Debatin KM. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 1999;18:1479-86.
48. van Noesel MM, Pieters R, Voute PA, Versteeg R. The N-myc paradox: N-myc overexpression in neuroblastomas is associated with sensitivity as well as resistance to apoptosis. Cancer Lett 2003;197:165-72.
49. Perini G, Diolaiti D, Porro A, Della Valle G. In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation. Proc Natl Acad Sci U S A 2005;102:12117-22.
50. Hansford LM, Thomas WD, Keating JM, et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A 2004;101:12664-9.
51. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16: 2985-95.
52. Cohn SL, Salwen H, Quasney MW, et al. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification. Oncogene 1990;5:1821-7.
53. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-8.